dr. reddy's labs glp-1 receptor agonist medications Laboratories has received approval from Health Canada for its generic semaglutide injection, strengthening the Indian drugmaker's presence in the fast-growing global market for diabetes therapies. The company said on Frontiers | Revisiting food addiction

Dr Reddys launches oral semaglutide biosimilar tablets, offering broader access to diabetes and weight-loss therapies in India.

Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant

The question is: How will we afford it?

Fast Absorbing with the GLP-1 Incorporate into your daily routine and advance your goals

Add psoriatic arthritis | 47 comments on LinkedIn